• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Companies that Ward Off ESG and Reputation Crises See Value Surge

    3/8/22 8:00:00 AM ET
    $APO
    $CVS
    $FB
    $JNJ
    Investment Managers
    Finance
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $APO alert in real time by email

    PITTSBURGH, March 8, 2022 /PRNewswire-PRWeb/ -- Companies with ESG and reputational risk protection strategies have seen their stock prices rise 5% above the market within two weeks of a reputational challenge, and that premium is almost double for companies that have publicly shared and validated those strategies.

    The study, by Steel City Re, an ESG and reputation insurer, also found that stock prices of firms that managed, validated and publicized ESG and reputation risk management strategies on average gained 9.3% over the subsequent seven months after a precipitating event, while firms in which such processes were in assumed by shareholders to be in place gained 4.3%. Companies that failed to institute, validate, and communicate risk management strategies lost 13.2% of their stock value over those seven-month periods, and they underperformed their peers by an average of 23.3%.

    "Investors appear to reward firms that actively manage reputational risks as operational strategies and not just potential PR problems," said Nir Kossovsky, Steel City Re's CEO. "Our study makes the case for ESG-focused firms to take a more structured, substantive and comprehensive approach to risk governance and management."

    "The data show that instituting, validating, and communicating risk management strategies can both fulfill the goals of stakeholder-centrism and meet shareholder expectations," he added.

    Illustrative highlights include:

    • Johnson & Johnson (NYSE:JNJ) outperformed the market by 16% ($1.7bn) when its much publicized strategic supply chain security and product safety processes were proven effective in 1986.
    • Rolls Royce (OTC:RYCEY), whose board defined its risk governance mission as protecting the reputation, viability, and profitability of the firm, outperformed the market by 14.9% ($3.4bn) after it proved the quality of its safety controls throughout its supply chain in 2011.
    • Apollo Global Management (NYSE:APO) outperformed the market by 16.6% ($1.9bn) after it announced an ESG-focused governance reorganization and presented in 2021 and independent validation of a 3-year investment in reputation risk management.
    • CVS (NYSE:CVS) outperformed the market by 9.3% ($8.6bn) when, presciently anticipating the ESG movement, it pursued an ethical innovative strategy that shunned tobacco products in 2014. It outperformed rivals Walgreens (NYSE:WBA) and Rite Aid (NYSE:RAD) by 16.6% and 24.8% respectively.
    • Apple (NADQ:AAPL) outperformed the market by 24% ($505bn) after introducing innovative ethical privacy features that addressed a critical ESG concern in the technology sector in 2021. It outperformed Meta (NYSE:FB), facing a range of privacy challenges, by 34.9%.

    About the Study

    The Steel Re study looked at seven firms that took direct action to publicize their reputation risk management and governance, 20 firms whose protection strategies were in assumed by shareholders to be in place because of their response to external events, 20 firms whose strategies were shown to be insufficient over seven months, and from among these, 22 firms whose reputational impairment and value losses were measured against peer competitors.

    The reputational challenges were all public events over the past 15 years supplemented by iconic cases of Johnson & Johnson's two Tylenol-related safety events of the 1980's. Individual gains and losses were calculated after normalizing for changes in the S&P500, and the date for ESG and reputational events was determined by a marked surge in stakeholder interest as explored in a related Steel City Re white paper.

    About Steel City Re

    Steel City Re provides parametric ESG insurance, reputational insurance and helps guide companies' boards and senior leadership in developing enhanced risk governance and management practices. Its underwriting model is supported by more than 7.3 million measures of reputational value and traditional financial metrics that also fuel ESG-focused hedge fund strategies. Its risk governance and management models are informed by principles of behavioral economics.

    Media Contact

    Desiree Niccoli, Steel City Re, 412-804-8649, [email protected]

    Steve Alschuler, Steel City Re, 917-647-2151, [email protected]

     

    SOURCE Steel City Re

    Get the next $APO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APO
    $CVS
    $FB
    $JNJ

    CompanyDatePrice TargetRatingAnalyst
    Apollo Global Management Inc. (New)
    $APO
    12/11/2025$186.00Buy
    UBS
    Apollo Global Management Inc. (New)
    $APO
    11/20/2025$180.00Equal-Weight → Overweight
    Morgan Stanley
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    CVS Health Corporation
    $CVS
    10/14/2025$91.00Buy
    Goldman
    Apollo Global Management Inc. (New)
    $APO
    10/3/2025$132.00Market Perform
    BMO Capital Markets
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $APO
    $CVS
    $FB
    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

    Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mutated mCSPC HORSHAM, Pa., Dec. 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1 Patients with BRCA mutations often have more aggressive forms of prostate cancer leading to poor prognosis, rep

    12/12/25 8:25:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CVS Health offering measles vaccine to South Carolina residents amid the state's current outbreak

    Unvaccinated residents can receive a measles vaccine at select CVS Pharmacy and MinuteClinic locations across the state WOONSOCKET, R.I., Dec. 11, 2025 /PRNewswire/ -- As South Carolina public health officials work to stop the spread of measles following the current outbreak in the state, CVS Health® (NYSE:CVS) is offering the measles-mumps-rubella (MMR) vaccine to residents. Both CVS Pharmacy® stores and MinuteClinic® walk-in medical clinics in the area have vaccines available to help protect patients against measles. According to the Centers for Disease Control and Preventio

    12/11/25 11:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Capital Power 2025 Investor Day: Accelerating Growth to 2030

    Announces MOU with Apollo-managed funds for US$3 billion investment partnership to pursue merchant U.S. natural gas generation acquisitions Enters into a binding MOU with investment-grade data centre developer in Alberta EDMONTON, Alberta, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Capital Power Corporation ("Capital Power" or the "Company") (TSX:CPX) is hosting its 2025 Investor Day today in Toronto. The event will highlight the Company's strategic priorities, 2030 growth targets, and 2026 guidance, underscoring Capital Power's position as a top-tier North American power producer serving the continent's growing electricity demand with reliable, efficient natural gas generation. 2025 Investor Da

    12/10/25 6:00:00 AM ET
    $APO
    Investment Managers
    Finance

    $APO
    $CVS
    $FB
    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/29/25 8:49:21 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Woods Eugene A.

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/11/25 5:02:15 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hewson Marillyn A

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/11/25 4:59:44 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pinto Daniel E

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/11/25 4:58:40 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Apollo Global Management with a new price target

    UBS resumed coverage of Apollo Global Management with a rating of Buy and set a new price target of $186.00

    12/11/25 9:02:43 AM ET
    $APO
    Investment Managers
    Finance

    Apollo Global Management upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Apollo Global Management from Equal-Weight to Overweight and set a new price target of $180.00

    11/20/25 7:57:06 AM ET
    $APO
    Investment Managers
    Finance

    Scotiabank initiated coverage on Johnson & Johnson with a new price target

    Scotiabank initiated coverage of Johnson & Johnson with a rating of Sector Outperform and set a new price target of $230.00

    11/13/25 9:14:21 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    SEC Filings

    View All

    CVS Health Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    12/9/25 6:33:11 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 8-K filed by CVS Health Corporation

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    11/20/25 4:18:11 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 13F-HR filed by Johnson & Johnson

    13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

    11/13/25 3:25:42 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    Financials

    Live finance-specific insights

    View All

    Capital Power 2025 Investor Day: Accelerating Growth to 2030

    Announces MOU with Apollo-managed funds for US$3 billion investment partnership to pursue merchant U.S. natural gas generation acquisitions Enters into a binding MOU with investment-grade data centre developer in Alberta EDMONTON, Alberta, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Capital Power Corporation ("Capital Power" or the "Company") (TSX:CPX) is hosting its 2025 Investor Day today in Toronto. The event will highlight the Company's strategic priorities, 2030 growth targets, and 2026 guidance, underscoring Capital Power's position as a top-tier North American power producer serving the continent's growing electricity demand with reliable, efficient natural gas generation. 2025 Investor Da

    12/10/25 6:00:00 AM ET
    $APO
    Investment Managers
    Finance

    Bridge Logistics Properties Acquires 1.1M SF Inland Empire Distribution Facility — One of the Largest Single Building Industrial Acquisitions in 2025

    BLP Capitalizes on Limited Supply of Million-Square-Foot Facilities to Strengthen Its National Logistics Platform Bridge Logistics Properties ("BLP"), subsidiary of Bridge Investment Group Holdings LLC (together with its affiliates, "Bridge"), announced the acquisition of a 1,101,900-square-foot Class A industrial distribution facility at 10681 Production Avenue in Fontana, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118958022/en/10681 Production Avenue - Fontana, California As one of the largest industrial acquisitions in the Inland Empire this year, the transaction underscores BLP's conviction in the long-t

    11/18/25 9:00:00 AM ET
    $APO
    Investment Managers
    Finance

    Apollo Reports Third Quarter 2025 Results

    NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Apollo Global Management, Inc. (NYSE:APO) (together with its consolidated subsidiaries, "Apollo") today reported results for the third quarter ended September 30, 2025. Marc Rowan, Chairman and Chief Executive Officer at Apollo said, "Our outstanding third quarter results reflect broad based momentum across the business. In a world of re-industrialization, aging populations, and investors seeking greater access to private markets, we are delivering with leading origination, new product solutions and distribution, and excess return for our clients. We are uniquely built to capitalize on these structural trends and our global team is making signif

    11/4/25 6:30:00 AM ET
    $APO
    Investment Managers
    Finance

    $APO
    $CVS
    $FB
    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Apollo Names Eiji Ueda Head of Asia Pacific as Firm Marks 20 Years in Region

    TOKYO and NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE:APO) today announced Mr. Eiji Ueda has been named a Partner and Head of Asia Pacific, succeeding Matt Michelini. Michelini, who has spearheaded Apollo's rapid expansion across the region since his appointment in 2022, will remain in region to oversee Ueda's transition before assuming broader leadership responsibilities with the firm next year. Ueda joins Apollo with demonstrated investment expertise and a nuanced understanding of Asia's evolving needs. He most recently served as Chief Investment Officer of Japan's Government Pension Investment Fund (GPIF), one of the largest institutional investors globally, where he led a

    10/15/25 8:05:00 PM ET
    $APO
    Investment Managers
    Finance

    Shutterfly Names Emily Whittaker Chief Executive Officer

    Sally Pofcher, Shutterfly's current CEO, to Transition After Leading Transformation and Setting Stage for Further Growth Shutterfly, the leading e-commerce company for personalized products and custom design, announced its current CEO, Sally Pofcher, will transition from the role of Chief Executive Officer as part of a planned succession. Emily Whittaker of VistaPrint will assume the role later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006485281/en/Emily Whittaker, former VistaPrint Executive Vice President of North America & Head of Global Marketing, assumes the role of Shutterfly CEO later this month. Sal

    10/6/25 1:00:00 PM ET
    $APO
    Investment Managers
    Finance

    $APO
    $CVS
    $FB
    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    10/18/24 12:45:41 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

    SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

    8/20/24 4:05:58 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples